Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
COMET - effectiveness and tolerability of methocarbamol versus oral opioid-analgesics as add-on measure in patients with non-specific low back pain refractory to recommended 1st line treatments. A retrospective analysis of depersonalized propensity score matched open-label real-world 4-week data from the German Pain e-Registry.
Ueberall MA, Mueller-Schwefe G. Ueberall MA, et al. Curr Med Res Opin. 2022 Feb;38(2):237-253. doi: 10.1080/03007995.2021.2003105. Epub 2021 Dec 14. Curr Med Res Opin. 2022. PMID: 34767467
Comparison of the Effectiveness and Tolerability of Nabiximols (THC:CBD) Oromucosal Spray versus Oral Dronabinol (THC) as Add-on Treatment for Severe Neuropathic Pain in Real-World Clinical Practice: Retrospective Analysis of the German Pain e-Registry.
Ueberall MA, Essner U, Vila Silván C, Mueller-Schwefe GHH. Ueberall MA, et al. Among authors: mueller schwefe ghh. J Pain Res. 2022 Feb 2;15:267-286. doi: 10.2147/JPR.S340968. eCollection 2022. J Pain Res. 2022. PMID: 35140513 Free PMC article.
Effectiveness, Safety, and Tolerability of Nabiximols Oromucosal Spray vs Typical Oral Long-Acting Opioid Analgesics in Patients with Severe Neuropathic Back Pain: Analysis of 6-Month Real-World Data from the German Pain e-Registry.
Ueberall MA, Vila Silván C, Essner U, Mueller-Schwefe GHH. Ueberall MA, et al. Among authors: mueller schwefe ghh. Pain Med. 2022 Apr 8;23(4):745-760. doi: 10.1093/pm/pnab263. Pain Med. 2022. PMID: 34480564 Free PMC article.
Efficacy and tolerability balance of oxycodone/naloxone and tapentadol in chronic low back pain with a neuropathic component: a blinded end point analysis of randomly selected routine data from 12-week prospective open-label observations.
Ueberall MA, Mueller-Schwefe GH. Ueberall MA, et al. Among authors: mueller schwefe gh. J Pain Res. 2016 Nov 11;9:1001-1020. doi: 10.2147/JPR.S112418. eCollection 2016. J Pain Res. 2016. PMID: 27881925 Free PMC article.
Safety and efficacy of oxycodone/naloxone vs. oxycodone vs. morphine for the treatment of chronic low back pain: results of a 12 week prospective, randomized, open-label blinded endpoint streamlined study with prolonged-release preparations.
Ueberall MA, Mueller-Schwefe GH. Ueberall MA, et al. Among authors: mueller schwefe gh. Curr Med Res Opin. 2015;31(7):1413-29. doi: 10.1185/03007995.2015.1047747. Epub 2015 May 29. Curr Med Res Opin. 2015. PMID: 25942606 Clinical Trial.
12 results